Business · 31/01/2013Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for XALKORI Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of Merck's cancer treatment drug XALKORI, following a submission to the US Department of Commerce's Director of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →